Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells
- 2 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 39 (20), 3997-4013
- https://doi.org/10.1038/s41388-020-1271-y
Abstract
Pancreatic cancer is one of the world’s leading causes of cancer-related death. Activation of STAT3 has been reported as a major contributor in pancreatic cancer tumorigenesis and chemoresistance. However, treatment of advanced pancreatic cancer patients with STAT3 inhibitors often meets drug resistance and heterogeneous response. We found that EGFR activation is a main cause for resistance to STAT3 inhibitors in pancreatic cancer cells, regardless of KRAS mutation status. Mechanistically, inhibition of STAT3 promotes STAT1- and STAT4-mediated TGF-α expression, leading to activation of the EGFR pathway. Combined treatment of pancreatic cancer cells with EGFR and STAT3 inhibitors persistently blocks EGFR and STAT3 signaling, and exerts synergistic antitumor activity both in vitro and in vivo, with or without KRAS mutation. Our results indicate that reciprocal cross-talk between STAT3 and EGFR pathways is a key molecular mechanism leading to resistance in pancreatic cancer cells. Furthermore, the study shows that combined inhibition of both EGFR and STAT3 might overcome drug resistance encountered during treatment with single agent alone. This study suggests an improved therapeutic strategy, through combined treatment with STAT3 and EGFR inhibitors, for pancreatic cancer patients.Funding Information
- National Natural Science Foundation of China (81672305)
- Wenzhou Science and Technology Project
- Medical Scientific Research Fund of Zhejiang Province
- Natural Science Foundation of Zhejiang Province (LY18H160047, LY17B020008)
This publication has 39 references indexed in Scilit:
- Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapiesTrends in Biochemical Sciences, 2014
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer CellsCancer Cell, 2014
- ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal CancerCell Reports, 2014
- HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian CancerCancer Research, 2014
- Novel Mechanistic Insights into Ectodomain Shedding of EGFR Ligands Amphiregulin and TGF-α: Impact on Gastrointestinal Cancers Driven by Secondary Bile AcidsCancer Research, 2014
- STAT heterodimers in immunityJAK-STAT, 2013
- Synthesis and anti-inflammatory evaluation of novel mono-carbonyl analogues of curcumin in LPS-stimulated RAW 264.7 macrophagesEuropean Journal of Medicinal Chemistry, 2010
- A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17Oncogene, 2010
- Role of STAT3 in Type I Interferon ResponsesOnline Journal of Public Health Informatics, 2006
- ADAMs: key components in EGFR signalling and developmentNature Reviews Molecular Cell Biology, 2005